| pubmed-article:17880055 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:17880055 | lifeskim:mentions | umls-concept:C0384601 | lld:lifeskim |
| pubmed-article:17880055 | lifeskim:mentions | umls-concept:C0243076 | lld:lifeskim |
| pubmed-article:17880055 | lifeskim:mentions | umls-concept:C1521827 | lld:lifeskim |
| pubmed-article:17880055 | lifeskim:mentions | umls-concept:C0205549 | lld:lifeskim |
| pubmed-article:17880055 | lifeskim:mentions | umls-concept:C2698650 | lld:lifeskim |
| pubmed-article:17880055 | pubmed:issue | 21 | lld:pubmed |
| pubmed-article:17880055 | pubmed:dateCreated | 2007-10-11 | lld:pubmed |
| pubmed-article:17880055 | pubmed:abstractText | The B1 receptor is an attractive target for the treatment of pain and inflammation. A series of 3-carboxamido-5-phenacylamino pyrazole B1 receptor antagonists are described that exhibit good potency against B1 and high selectivity over B2. Initially, N-unsubstituted pyrazoles were studied, but these compounds suffered from extensive glucuronidation in primates. This difficulty could be surmounted by the use of N-substituted pyrazoles. Optimization efforts culminated in compound 41, which has high receptor potency and metabolic stability. | lld:pubmed |
| pubmed-article:17880055 | pubmed:language | eng | lld:pubmed |
| pubmed-article:17880055 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17880055 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:17880055 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17880055 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17880055 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17880055 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:17880055 | pubmed:month | Oct | lld:pubmed |
| pubmed-article:17880055 | pubmed:issn | 0022-2623 | lld:pubmed |
| pubmed-article:17880055 | pubmed:author | pubmed-author:TungJay SJS | lld:pubmed |
| pubmed-article:17880055 | pubmed:author | pubmed-author:WuJingJ | lld:pubmed |
| pubmed-article:17880055 | pubmed:author | pubmed-author:GarofaloAlber... | lld:pubmed |
| pubmed-article:17880055 | pubmed:author | pubmed-author:WoneDavid W... | lld:pubmed |
| pubmed-article:17880055 | pubmed:author | pubmed-author:PleissMichael... | lld:pubmed |
| pubmed-article:17880055 | pubmed:author | pubmed-author:DressenDarren... | lld:pubmed |
| pubmed-article:17880055 | pubmed:author | pubmed-author:HawkinsonJonJ | lld:pubmed |
| pubmed-article:17880055 | pubmed:author | pubmed-author:HomDennisD | lld:pubmed |
| pubmed-article:17880055 | pubmed:author | pubmed-author:JagodzinskiJa... | lld:pubmed |
| pubmed-article:17880055 | pubmed:author | pubmed-author:MaruggJennife... | lld:pubmed |
| pubmed-article:17880055 | pubmed:author | pubmed-author:NeitzelMartin... | lld:pubmed |
| pubmed-article:17880055 | pubmed:author | pubmed-author:SzokeBalazsB | lld:pubmed |
| pubmed-article:17880055 | pubmed:author | pubmed-author:ZhangHeatherH | lld:pubmed |
| pubmed-article:17880055 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:17880055 | pubmed:day | 18 | lld:pubmed |
| pubmed-article:17880055 | pubmed:volume | 50 | lld:pubmed |
| pubmed-article:17880055 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:17880055 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:17880055 | pubmed:pagination | 5161-7 | lld:pubmed |
| pubmed-article:17880055 | pubmed:meshHeading | pubmed-meshheading:17880055... | lld:pubmed |
| pubmed-article:17880055 | pubmed:meshHeading | pubmed-meshheading:17880055... | lld:pubmed |
| pubmed-article:17880055 | pubmed:meshHeading | pubmed-meshheading:17880055... | lld:pubmed |
| pubmed-article:17880055 | pubmed:meshHeading | pubmed-meshheading:17880055... | lld:pubmed |
| pubmed-article:17880055 | pubmed:meshHeading | pubmed-meshheading:17880055... | lld:pubmed |
| pubmed-article:17880055 | pubmed:meshHeading | pubmed-meshheading:17880055... | lld:pubmed |
| pubmed-article:17880055 | pubmed:meshHeading | pubmed-meshheading:17880055... | lld:pubmed |
| pubmed-article:17880055 | pubmed:meshHeading | pubmed-meshheading:17880055... | lld:pubmed |
| pubmed-article:17880055 | pubmed:meshHeading | pubmed-meshheading:17880055... | lld:pubmed |
| pubmed-article:17880055 | pubmed:meshHeading | pubmed-meshheading:17880055... | lld:pubmed |
| pubmed-article:17880055 | pubmed:year | 2007 | lld:pubmed |
| pubmed-article:17880055 | pubmed:articleTitle | Preparation and optimization of a series of 3-carboxamido-5-phenacylaminopyrazole bradykinin B1 receptor antagonists. | lld:pubmed |
| pubmed-article:17880055 | pubmed:affiliation | Elan Pharmaceuticals, Inc., 800 Gateway Boulevard, South San Francisco, California 94080, USA. al.garofalo@elan.com | lld:pubmed |
| pubmed-article:17880055 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:17880055 | pubmed:publicationType | In Vitro | lld:pubmed |
| http://linkedlifedata.com/r... | http://linkedlifedata.com/r... | pubmed-article:17880055 | lld:chembl |
